SVRA
Savara Inc
NASDAQ · Biotechnology
$5.30
+0.14 (+2.71%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 135.25M | 127.87M | 115.53M |
| Net Income | 19.67M | 13.91M | 14.59M |
| EPS | — | — | — |
| Profit Margin | 14.5% | 10.9% | 12.6% |
| Rev Growth | +10.1% | -5.7% | +15.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 259.00M | 309.68M | 318.59M |
| Total Equity | 684.41M | 677.59M | 605.99M |
| D/E Ratio | 0.38 | 0.46 | 0.53 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 27.67M | 31.26M | 23.85M |
| Free Cash Flow | 12.49M | 17.00M | 15.12M |